Abstract
Two applications describe 1-(heteroarylmethoxybenzoyl)-2-methylindolylacetic acid derivatives that are active as prostaglandin D2 receptor (DP) antagonists. Both indol-3-ylacetic acid and indol-4-ylacetic acid derivatives have good affinity for the DP receptor. The use of these antagonists for the treatment of various inflammatory diseases is claimed but the preferred indication is allergic rhinitis, with the development compound by Ono Pharm., ONO4217Na, likely to be described in one of the applications.